The one entry here that is not about how a drug is handled once it is inside you. It is about whether it gets inside you at all — a medicine that tastes unbearably bitter to one child and merely unpleasant to another is a real adherence problem with a genetic explanation.
This is about whether a medicine can be swallowed, not about how it is handled once it is. TAS2R38 genotype changes how bitter a bitter drug tastes, and in a retrospective analysis of 448 children, those carrying at least one bitter-sensitive allele (PP or AP) were more likely to have taken medication in solid form than bitter-insensitive (AA) children — a liquid that tastes intensely bitter tends to be refused. A later study found the differing bitterness of chloramphenicol and ofloxacin was explained by TAS2R38 diplotype and a TAS2R9 variant respectively. No guideline uses genotype to choose a formulation; this explains a real difficulty rather than instructing anyone.
Lipchock SV, Reed DR, Mennella JA, Clin Ther 2012;34:728-33, PMID 22440514; Front Genet 2022;13:960154, PMID 35967977
These are the positions in your own file that carry the genes above. Not every gene in a guideline is one we report — where that is the case the gene appears above without a variant here, and the note says so.
TAS2R38 · rs1726866
Read more →TAS2R38 · rs10246939
Read more →TAS2R38 · rs713598
Read more →